Instadose is facing a class action lawsuit alleging that the Company made materially false and/or misleading statements and/or failed to disclose that:
(i) Instadose had performed inadequate due diligence into the business combination with Instadose Canada and/or ignored significant red flags associated with Instadose Canada; (ii) Instadose’s internal controls and policies were inadequate to detect and/or prevent impermissible trading activity by control persons of the Company; (iii) the foregoing subjected Instadose to a heightened risk of regulatory scrutiny and enforcement action; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you incurred a loss on INSD stocks purchased between December 8, 2020 and November 24, 2021, this lawsuit is on your behalf. The lawsuit was filed in the United States District Court for the Eastern District of Virginia, and our firm is reaching out to investors to discuss their legal rights.
If you wish to act as a representative of the shareholders harmed by this misconduct, you may ask the court to appoint you as lead plaintiff. A lead plaintiff directs the litigation and participates in important decisions, including whether to accept a settlement for the class in the action.
You only have until February 28, 2022 to apply to be lead plaintiff. The court will then evaluate the applicants and choose a lead plaintiff. You are not required to act as a lead plaintiff in order to participate in any recovery.
Enter the following information for this class action case- the deadline is approaching.